Table 2 Basic parameters in subgroups.

From: Detection of aqueous VEGF concentrations before and after intravitreal injection of anti-VEGF antibody using low-volume sampling paper-based ELISA

 

Group 1 (n = 16) Before IVI

Group 2 (n = 15) Post-IVI  ≤ 5 weeks

Group 3 (n = 15) Post-IVI > 5 weeks

P-value

1 vs 2

1 vs 3

2 vs 3

Age (mean ± SD)

79.63 ± 7.88

75.33 ± 8.38

76.47 ± 10.35

0.15

0.34

0.74a

Female/male

4/12

6/9

4/11

0.46

1.00

0.70b

Latest IVI avastin/lucentis

not applicable

9/6

11/4

0.70a

AMD/myopic NV/PCV

15/0/1

12/2/1

14/0/1

0.33

1.00

0.60a

Follow-up months (mean ± SD)

14.38 ± 6.89

12.14 ± 6.67

18.00 ± 11.30

0.37

0.29

0.09a

No. of samples below detection limit of VEGF after IVI

0

9 (60%)

2 (13.3%)

< 0.05*b

  1. aKruskal-Wallis test.
  2. bFisher’s two-tailed test.
  3. IVI = intravitreal injection, AMD = age-related macular degeneration, NV = neovascularization, PCV = polypoidal choroidal vasculopathy, VEGF = vascular endothelial growth factor, SD = standard deviation.